MmpL3 drug discovery in Mycobacterium abscessus: from target validation to therapeutic development
Abstract
Mycobacterium abscessus (Mab) pulmonary disease remains difficult to treat because of extensive intrinsic resistance, the limited bactericidal activity of current drugs, and the physiological diversity of bacterial populations encountered during infection. MmpL3, an essential transporter required for trehalose monomycolate (TMM) trafficking during mycomembrane assembly, has emerged as one of the best-characterized experimental drug targets in M. abscessus. Chemically distinct MmpL3-directed series include piperidinols, indole-2-carboxamides, benzimidazoles, benzothiazole amides, and naphthalen-1-ylmethanamines. Across these series, resistance genetics and mycolate transport phenotypes support MmpL3 engagement, although the nature and strength of the supporting evidence differ among chemotypes. Some compounds predominantly disrupt TMM transport and cell envelope assembly, whereas others additionally alter membrane integrity, adenosine triphosphate (ATP) homeostasis, or respiration. These observations show that target identity alone does not define the full antibacterial mechanism of an MmpL3 inhibitor. In this study, we integrate the chemical, genetic, biochemical, and physiological evidence defining MmpL3 inhibition in M. abscessus and discuss how chemotype-specific resistance and cellular pharmacology may influence bactericidal activity, combination therapy, and lead optimization. We argue that future MmpL3-directed drug development should prioritize not only potency but also bactericidal activity, resistance resilience, and pharmacological compatibility with multidrug regimens.
Related
- Genome-wide evolutionary shifts shape the emergence of dominant circulating clones in Mycobacterium abscessus
- Application of the ORBIT Protocol for Targeted Gene Deletion to Mycobacterium abscessus
- Modifications to a vegan artificial honey result in inhibitory activity against Mycobacterium abscessus
- Cryo-electron microscopy structure of Jabs, a bacteriophage infecting the multidrug-resistant pathogen Mycobacterium abscessus
- Iron-sulfur cluster delivery by SufT enables oxidative stress resistance and intracellular survival in Mycobacterium abscessus
BibTeX
@article{heo2026mmpl3,
title = {{MmpL3 drug discovery in Mycobacterium abscessus: from target validation to therapeutic development}},
author = {Bo Eun Heo and Yubin Lee and Anwesha Ash and Cheol Moon and Jichan Jang},
journal = {Frontiers in Microbiology},
year = {2026},
month = nov,
doi = {10.3389/fmicb.2026.1992782},
url = {https://www.frontiersin.org/articles/10.3389/fmicb.2026.1992782},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - MmpL3 drug discovery in Mycobacterium abscessus: from target validation to therapeutic development
AU - Bo Eun Heo
AU - Yubin Lee
AU - Anwesha Ash
AU - Cheol Moon
AU - Jichan Jang
PY - 2026
DA - 2026/11/09
JO - Frontiers in Microbiology
DO - 10.3389/fmicb.2026.1992782
UR - https://www.frontiersin.org/articles/10.3389/fmicb.2026.1992782
AB - Mycobacterium abscessus (Mab) pulmonary disease remains difficult to treat because of extensive intrinsic resistance, the limited bactericidal activity of current drugs, and the physiological diversity of bacterial populations encountered during infection. MmpL3, an essential transporter required for trehalose monomycolate (TMM) trafficking during mycomembrane assembly, has emerged as one of the best-characterized experimental drug targets in M. abscessus. Chemically distinct MmpL3-directed series include piperidinols, indole-2-carboxamides, benzimidazoles, benzothiazole amides, and naphthalen-1-ylmethanamines. Across these series, resistance genetics and mycolate transport phenotypes support MmpL3 engagement, although the nature and strength of the supporting evidence differ among chemotypes. Some compounds predominantly disrupt TMM transport and cell envelope assembly, whereas others additionally alter membrane integrity, adenosine triphosphate (ATP) homeostasis, or respiration. These observations show that target identity alone does not define the full antibacterial mechanism of an MmpL3 inhibitor. In this study, we integrate the chemical, genetic, biochemical, and physiological evidence defining MmpL3 inhibition in M. abscessus and discuss how chemotype-specific resistance and cellular pharmacology may influence bactericidal activity, combination therapy, and lead optimization. We argue that future MmpL3-directed drug development should prioritize not only potency but also bactericidal activity, resistance resilience, and pharmacological compatibility with multidrug regimens.
SN - 1664-302X
ER -